Jihad Obeid was appointed as assistant vice president for research for AI Strategy & Research Intelligence at the Medical University of South Carolina.
Mark Veich was namedchief organizational advancement officer at the Parker Institute for Cancer Immunotherapy.
Christopher J. Liekweg was namedassociate director for administration and chief department administrator at the University of Michigan Rogel Cancer Center.
Vincent Wu was named a Caspar Wistar Fellow at the Wistar Institute’s Vaccine & Immunotherapy Center.
The University of Arkansas for Medical Sciences received a $10.5 million NIH grant to develop biomarkers for all human diseases, including cancer, through proteomics.
A clinical guideline from the American Society for Radiation Oncology is the first to focus on radiation therapy for patients with gastric cancer. The recommendations outline radiation therapy’s role in multidisciplinary care, including best practices for patient selection, integration with systemic therapy, and treatment delivery.
For the first time in decades, more people in the Bronx nearby Montefiore Einstein Comprehensive Cancer Center are being diagnosed with stage 1, versus stage 4 lung cancer.
A new generation of targeted treatments and gentler chemotherapy options for older adults with a new diagnosis of acute myeloid leukemia is driving better survival and cure rates.
Substantial delays are taking place across the cancer care pathway in Nepal, with many patients waiting months between first symptoms and treatment, according to an article by the International Agency for Research on Cancer and partners.
FDA approved Keytruda (pembrolizumab) and Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) in combination with Padcev (enfortumab vedotin-ejfv), as neoadjuvant treatment and then continued after cystectomy as adjuvant treatment, for the treatment of adult patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy. These approvals represent the first PD-1 inhibitor plus ADC regimens for this patient population.
